STOCK TITAN

INTELLIGENT BIO SOLUTIONS (INBS) SEC Filings, May-Aug 2026

INBS NASDAQ

Intelligent Bio Solutions Inc. filings document a medical technology issuer commercializing rapid, non-invasive fingerprint sweat drug screening and reporting through periodic material-event disclosures. Recent 8-Ks cover operating results, preliminary revenue information, Regulation FD presentations, clinical study program updates tied to the Intelligent Fingerprinting Drug Screening System, and manufacturing disclosures for readers and lateral-flow test strips.

The filing record also includes capital-structure and governance subjects, including common stock issued through warrant exercises and an at-the-market offering agreement, restricted stock awards under the 2019 Long Term Incentive Plan and Australian Sub-Plan, and Nasdaq Capital Market bid-price compliance notices. These disclosures frame the company's product commercialization, regulatory pathway, equity compensation, share count and listing-status matters.

Rhea-AI Summary

Intelligent Bio Solutions Inc. reported completion of a Usability Study for its Intelligent Fingerprinting Drug Screening System, supporting an FDA 510(k) submission for U.S. market clearance to detect the opiate codeine. The study, run with CenExel Clinical Research, followed FDA guidance and ICH GCP standards.

The study evaluated how easily workplace operators can be trained to use the system; 15 operators with no specialist laboratory background successfully participated, reinforcing that the system can be administered by non-specialists. This Usability Study is part of a broader 510(k) program that also includes cut-off, method comparison, interference, precision and penetration testing. The company states it remains on track to submit its 510(k) package in calendar H2 2026 as it moves toward planned entry into the multi-billion-dollar U.S. drug screening market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.10%
Tags
current report
-
Rhea-AI Summary

Intelligent Bio Solutions Inc. reported completion of an Interference Study for its Intelligent Fingerprinting Drug Screening System, a key element supporting an FDA 510(k) submission for U.S. market clearance to detect the opiate codeine.

The study, conducted with CenExel Clinical Research, Inc. under FDA guidance and ICH GCP standards, tested whether everyday substances such as hand creams, alcohol-based products, oils, dirt, and water affect test accuracy. Data analysis is underway, with independent verification via LC-MS/MS. The Interference Study forms part of a broader program including clinical cut-off, method comparison, precision, and penetration testing, and the company states it remains on track to submit its 510(k) package in calendar H2 2026 as it works toward entry into the multi-billion-dollar U.S. drug screening market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.55%
Tags
current report
-
Rhea-AI Summary

Intelligent Bio Solutions Inc. reported that its total outstanding common stock was 3,018,188 shares as of the close of business on July 31, 2026. This updated share count reflects sales under an At The Market Offering Agreement, exercises of previously issued warrants, and issuances of restricted shares under an investor relations and corporate development advisory agreement.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.55%
Tags
current report
Rhea-AI Summary

Intelligent Bio Solutions Inc. reports that it has addressed all cybersecurity and software-related review items for its planned FDA 510(k) submission for the Intelligent Fingerprinting Drug Screening System. This follows independent third-party penetration testing, with 100% of medium-risk vulnerabilities remediated and low-risk items reduced from 11 to 2, supported by risk-based justifications that remaining issues do not affect device safety, effectiveness, or performance.

The company has also fully resolved all 19 software bill of materials (SBOM) vulnerabilities, aligning documentation and system configuration with FDA guidance and obtaining independent verification that no issues remain. Management states these steps materially reduce regulatory risk and strengthen its 510(k) package, which is on track for submission in calendar H2 2026, initially targeting codeine detection in a multi-billion-dollar U.S. drug screening market. A manufacturing partnership with Syrma Johari MedTech is expected to deliver more than 40% annual production cost savings and approximately 20 percentage-point gross margin improvement to support a scalable U.S. launch following potential FDA clearance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.31%
Tags
current report
-
Rhea-AI Summary

Intelligent Bio Solutions Inc. reported completing extensive precision testing to support its planned FDA 510(k) submission for U.S. market clearance of its Intelligent Fingerprinting Drug Screening System for detection of the opiate codeine.

The precision program covered more than 1,600 tests across three production runs and three independent sites, demonstrating repeatable, reproducible performance suited to workplace and other drug screening environments. These data, together with penetration testing and prior Cut-off, Method Comparison, and Interference Studies, form a comprehensive package addressing safety, accuracy, usability, specificity, security, and precision. The company describes the U.S. drug screening market as a multi‑billion‑dollar annual opportunity and highlights rapid, non‑invasive fingerprint testing with results in under ten minutes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.12%
Tags
current report
-
Rhea-AI Summary

Intelligent Bio Solutions Inc. filed a current report describing a new Interference Study to support its FDA 510(k) submission for U.S. clearance of its Intelligent Fingerprinting Drug Screening System for detecting the opiate codeine. The company has partnered with CenExel Clinical Research to run the study with 75 healthy adult participants under undosed and dosed conditions while handling common substances that might affect results.

The study is designed to show the system maintains specificity for codeine and avoids false positives or negatives, with samples confirmed by LC‑MS/MS analysis. It will run alongside a Method Comparison Study and follows a Cut-off Study that began in January 2026. Intelligent Bio Solutions expects to finish the Interference Study by mid‑July 2026 and include the data in its FDA 510(k) submission package.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.17%
Tags
current report
Rhea-AI Summary

Intelligent Bio Solutions Inc. is starting a multi-site Method Comparison Study to support an FDA 510(k) submission for U.S. clearance of its Intelligent Fingerprinting Drug Screening System for the opiate codeine. The company is working with CenExel Clinical Research to test the system’s accuracy when used by typical workplace screening staff.

The study will enroll 135 donor participants and use nine operator participants to mirror real-world employment and safety-sensitive settings. Key metrics such as sensitivity, specificity, and overall accuracy will be confirmed using LC-MS/MS, and enrollment and data collection are expected to finish by the end of July 2026, with results included in the company’s 510(k) package.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.42%
Tags
current report
-
Rhea-AI Summary

INTELLIGENT BIO SOLUTIONS INC. ownership disclosure: Armistice Capital, LLC and Steven Boyd report beneficial ownership of 163,571 shares of Common Stock, representing 9.99% of the class. The filing states Armistice Capital exercises shared voting and dispositive power over these shares under an Investment Management Agreement.

The report is a joint Schedule 13G filing executed by Steven Boyd on 05/15/2026 and identifies Armistice Capital Master Fund Ltd. as the direct holder while the Master Fund disclaims direct beneficial ownership due to the Investment Management Agreement.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.43%
Tags
ownership
-
Rhea-AI Summary

Intelligent Bio Solutions Inc. reported strong fiscal third quarter 2026 growth, with revenue of $1.06 million, up 46% year-over-year, and nine-month revenue of $3.07 million, up 39%.

Gross profit margin improved to 50.5% in Q3 and 49.3% for the nine months, about 800 basis points higher than a year earlier, driven mainly by higher-margin cartridge sales. Despite this progress, the company still posted a Q3 net loss of $2.86 million and a nine-month net loss of $8.52 million, although cash and cash equivalents increased to $6.86 million as of March 31, 2026, helped by capital raising.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.01%
Tags
current report
Rhea-AI Summary

Intelligent Bio Solutions Inc. reported strong revenue growth but continued losses for the quarter and nine months ended March 31, 2026. Revenue rose to $1.06 million for the quarter and $3.07 million for nine months, representing approximately 46% and 39% increases over the prior-year periods, driven by new customers and higher cartridge reorders. Gross margin improved to about 50% for the quarter and 49% for nine months as volumes and product mix shifted toward higher-margin consumables.

Despite this, the company posted a nine‑month net loss of $8.55 million and used $8.74 million of cash in operating activities. Cash and cash equivalents were $6.86 million as of March 31, 2026, with shareholders’ equity of $8.75 million. Management states there is substantial doubt about the company’s ability to continue as a going concern over the next 12 months without additional financing and expects ongoing operating losses.

To support liquidity, the company raised capital through an at‑the‑market program and warrant exercises, and completed a December 2025 private placement with gross proceeds of about $10.0 million. Common shares outstanding increased to 2,391,846 as of May 12, 2026, reflecting significant equity issuance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25.47%
Tags
quarterly report

FAQ

How many INTELLIGENT BIO SOLUTIONS (INBS) SEC filings are available on StockTitan?

StockTitan tracks 72 SEC filings for INTELLIGENT BIO SOLUTIONS (INBS), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for INTELLIGENT BIO SOLUTIONS (INBS)?

The most recent SEC filing for INTELLIGENT BIO SOLUTIONS (INBS) was filed on November 10, 2026.